|
Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche/Genentech |
Speakers' Bureau - GlaxoSmithKline; Novartis; Roche/Genentech |
|
|
Honoraria - Clovis Oncology; Roche |
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Roche |
Research Funding - AstraZeneca (Inst) |
|
|
No Relationships to Disclose |
|
|
Research Funding - Avon Foundation; NCI; NCI, Susan G. Komen, Avon; Susan G. Komen for the Cure |
|
|
Consulting or Advisory Role - Brocade |
|
|
No Relationships to Disclose |
|
|
Honoraria - Novartis; Sanofi |
Consulting or Advisory Role - NanoString Technologies; Novartis; Roche |
Speakers' Bureau - AstraZeneca; Eisai; Roche |
Research Funding - Abbvie; Bayer; Celgene; Novartis; Tesaro |
|
|
|
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
Patents, Royalties, Other Intellectual Property - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbott Diagnostics; Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbott Diagnostics; Abbvie |